Covalent modification of the oncogene product Mdm2 by the ubiquitin-related protein SUMO1 protects it from ubiquitination and enhances its E3 ligase activity towards p53 in vitro. Disappearance of ...

However, loss of p53 tumour-suppressor activity can also occur through amplification of MDM2. As MDM2 is a negative regulator of p53, this promotes p53 degradation and inhibits p53 tumour ...

MDM2, on the other hand, is one of the most frequently studied oncogenes and is an excellent target for cancer therapy, based on its p53-dependent and p53-independent oncogenic activities in ...

为探究 MDM2 启动子多态性对乳腺癌患者化疗时骨髓功能的影响，作者[第一作者单位] 研究人员开展相关研究，发现 SNP309 和 del1518 与中性粒细胞恢复有关。该成果为化疗方案优化提供新思路，值得科研读者一读。 在医学研究的广阔领域中，有一个神秘的 “小宇宙 ...

Researchers from Walter and Eliza Hall Institute of Medical Research, The University of Melbourne and affiliated organizations presented the development of a new reporter mouse model designed to study ...

Under normal, unstressed conditions, a key negative regulator of p53 is MDM2, which binds to the transactivation domain of p53 and ubiquitylates the protein, targeting it for degradation.

Previous research revealed that nuclear factor of activated T cells 1 (NFAT1) is a novel regulator of the mouse double minute 2 homolog (MDM2) oncogene, which acts by directly binding to the MDM2 P2 ...